Holen Sie sich die Stockscreener-App
3.30
2.08%
-0.07
Handel nachbörslich:
3.52
0.22
+6.67%
Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten
Prelude Therapeutics Inc. Files Form 8-K with SEC – Company Information and Legal Exhibit Details (March 12, 2026) - Minichart
Prelude Therapeutics files to offer up to $25 million in stock through Jefferies - Investing.com
Prelude Therapeutics 2025 Annual Report: Precision Oncology Pipeline, Business Strategy, and Regulatory Overview - Minichart
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8% - AlphaStreet
Prelude Therapeutics (NASDAQ:PRLD) Price Target Raised to $6.00 at Citizens Jmp - MarketBeat
Citizens Analyst Raises Price Target for Prelude Therapeutics (P - GuruFocus
Citizens raises Prelude Therapeutics price target on JAK2 potential By Investing.com - Investing.com Canada
Prelude Therapeutics (PRLD) Q4 Loss Per Share Narrows Challenging Longstanding Bearish Narratives - simplywall.st
Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings - AlphaStreet
Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M - AlphaStreet
Prelude Therapeutics Inc (PRLD) Reports Wider Loss for FY25 vs. Estimates - AlphaStreet
Prelude Therapeutics 2025 10-K: Revenue $12.14M, EPS (1.29) - TradingView
Prelude Therapeutics (NASDAQ:PRLD) Posts Quarterly Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
PRLD: Secured $60M upfront from Incyte, boosting cash and extending runway into Q2 2027 - TradingView
Prelude Therapeutics (PRLD) Advances Key Drug Programs with IND Clearance - GuruFocus
Prelude Therapeutics Earnings Report: Q4 Overview - Benzinga
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 - GlobeNewswire
Aug Analyst Calls: Can Prelude Therapeutics Incorporated outperform under higher oil prices2025 Risk Factors & Fast Gain Swing Alerts - baoquankhu1.vn
Prelude Therapeutics Inc expected to post a loss of 3 cents a shareEarnings Preview - TradingView
Volume Report: Is Prelude Therapeutics Incorporated a cyclical or defensive stockQuarterly Earnings Report & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Prelude Therapeutics (PRLD) Expected to Announce Earnings on Monday - MarketBeat
PRLD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Market Wrap: Is Prelude Therapeutics Incorporated backed by strong institutional buyingMarket Performance Summary & Expert Verified Movement Alerts - baoquankhu1.vn
Quarterly Risk: Does Prelude Therapeutics Incorporated have consistent dividend growthJuly 2025 Earnings & Safe Capital Allocation Plans - baoquankhu1.vn
PRLDPrelude Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Guidance Update: Is Prelude Therapeutics Incorporated stock trending bullishTreasury Yields & Technical Entry and Exit Alerts - baoquankhu1.vn
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update - MarketBeat
How Prelude Therapeutics’ deal with Incyte changed its course - Delaware Business Times
What’s the beta of Prelude Therapeutics Incorporated stock2025 AllTime Highs & AI Powered Market Entry Strategies - mfd.ru
Aug Chart Watch: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Is Prelude Therapeutics Incorporated a cyclical or defensive stock2025 Sector Review & High Accuracy Swing Entry Alerts - mfd.ru
Is Prelude Therapeutics Incorporated in a long term uptrendJuly 2025 Market Mood & Technical Buy Zone Confirmation - mfd.ru
Prelude Therapeutics (NASDAQ:PRLD) Trading Down 0.9%Should You Sell? - MarketBeat
Is Prelude Therapeutics Incorporated stock trending bullishWeekly Profit Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Prelude Therapeutics Secures FDA Clearance for Key Drug Candidate - AD HOC NEWS
Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected - RTTNews
Take Profit: Does Prelude Therapeutics Incorporated have a sustainable dividendTrade Analysis Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Why Did PRLD Stock Surge 13% Today? - Stocktwits
Aug Wrap: Is ETRACS 2xMonthly Pay Leveraged Index ETN benefiting from interest rate changes2025 Market WrapUp & Weekly Stock Breakout Alerts - baoquankhu1.vn
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up - GlobeNewswire
Why did PRLD stock surge 13% today? - MSN
Prelude’s JAK2 V617F inhibitor PRT-12396 gains IND clearance - BioWorld MedTech
Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens - Investing.com Canada
FDA clears Prelude Therapeutics’ IND for JAK2 inhibitor in blood disorders - Investing.com Canada
Prelude Therapeutics (PRLD) Advances Blood Cancer Drug Trial wit - GuruFocus
Prelude Therapeutics Incorporated Receives FDA Clearance of Investigational New Drug Application for PRT12396 - marketscreener.com
Prelude Therapeutics stock surges after FDA clears IND for cancer drug By Investing.com - Investing.com South Africa
Prelude climbs as FDA clears study for Incyte-partnered cancer candidate - Seeking Alpha
Prelude Therapeutics stock surges after FDA clears IND for cancer drug - Investing.com India
Prelude Therapeutics receives FDA clearance of investigational new drug application (IND) for PRT12396, a mutant-selective JAK2V617F inhibitor - marketscreener.com
Prelude Therapeutics (PRLD) Gains FDA Approval for Phase 1 Study of PRT12396 - GuruFocus
Prelude Therapeutics Wins FDA IND Clearance for PRT12396 - TipRanks
Prelude Therapeutics Inc FDA Clearance for PRT12396 Phase 1 Study - TradingView
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor - ChartMill
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):